Nanologica has received an order of appx. SEK 2 million for the company’s silica-based purification media NLAB Saga®. The customer is a manufacturer of peptide drugs, and the order relates to evaluation of NLAB Saga® on a production scale.
Nanologica’s team has been working with this customer for a few years, including carrying out an extensive application development project for them. With this order, the customer will proceed to evaluate NLAB Saga® on a production scale.
“After working with this customer for a long time, it is now very pleasing that we received this order which clearly shows that the customer is satisfied with our product quality and now wants to evaluate on a production scale to be able to include it in their manufacturing. It is also gratifying that this order relates to a particle size that is generally used by insulin manufacturers, which again indicates that we will be able to sell our different product types and not just the one that is generally used for purification of GLP-1 analogues. Our team has done a fantastic job with this customer and we look forward to continuing the work of streamlining our customers’ workflows when it comes to purification of peptide-based drugs”, comments Nanologica’s CEO Andreas Bhagwani.
The order value amounts to appx. SEK 2 million at today’s exchange rate and will be delivered immediately.